2/26
08:13 am
ifrx
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Low
Report
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
2/26
07:30 am
ifrx
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
Low
Report
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
1/29
07:30 am
ifrx
InflaRx Announces Participation in February Investor Conferences
Low
Report
InflaRx Announces Participation in February Investor Conferences
1/8
08:00 am
ifrx
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
Medium
Report
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
12/31
12:13 pm
ifrx
InflaRx (NASDAQ:IFRX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
InflaRx (NASDAQ:IFRX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/30
10:54 am
ifrx
InflaRx (NASDAQ:IFRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
InflaRx (NASDAQ:IFRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
12/30
07:30 am
ifrx
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
Medium
Report
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
12/16
04:37 pm
ifrx
InflaRx (NASDAQ:IFRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
InflaRx (NASDAQ:IFRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
07:30 am
ifrx
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
Low
Report
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
12/4
07:18 am
ifrx
InflaRx (NASDAQ:IFRX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Medium
Report
InflaRx (NASDAQ:IFRX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.